Search results for "PARP"

showing 10 items of 39 documents

530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pami…

2020

Oncologymedicine.medical_specialtyTemozolomidebusiness.industryLow doseLocally advancedHematologyPARP1OncologyInternal medicinemedicineBiomarker (medicine)businessmedicine.drugAnnals of Oncology
researchProduct

The Activity of the Nucleosome Remodeling ATPase ISWI is Regulated by poly-ADP-ribosylation

2008

PARP ISWI
researchProduct

The Nucleosome Remodeling ATPase ISWI is Regulated by poly-ADP-ribosylation

2008

PARP ISWI
researchProduct

Regulation of Chromatin Remodeling through poly-ADP-ribosylation

2008

PARP ISWI Chromatin Remodelling
researchProduct

The Poly-ADP-Ribose Polymerase PARP Modulates the Activity of the Nucleosome Remodeling ATPase ISWI

2008

PARP ISWI Chromatin Remodelling
researchProduct

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art

2022

: Ovarian cancer represents the fifth cause of cancer death among women, carrying one of the worst prognoses among gynaecological malignancies. The need to achieve no residual disease after surgery in order to optimize prognosis of advanced-stage ovarian cancer introduced the idea of neoadjuvant chemotherapy. The present review aims to summarize current state-of-the-art evidence regarding the efficacy and safety of neoadjuvant chemotherapy as well as novel insights regarding the usage of modern therapeutic regimens in the context of neoadjuvant chemotherapy. The last decade has been characterized by the breakthrough scientific evidence that neoadjuvant chemotherapy followed by interval debu…

PARP inhibitorOvarian cancerEndocrinology Diabetes and MetabolismObstetrics and Gynecologystate of the artDiagnostic laparoscopyNeoadjuvant chemotherapySettore MED/40 - Ginecologia E OstetriciaMenopausal Review
researchProduct

In Human Retinoblastoma Y-79 Cells 3-aminobenzamide induces Differentiation

2006

PARP inhibitorRetinoblastomadifferentiation
researchProduct

Differentiative pathway activated by 3-aminobenzamide in human osteosarcoma MG-63 cells involves FAK and PAK activities.

2006

PARP inhibitorosteosarcomafocal adhesions
researchProduct

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

2019

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1…

PBD Polo box domainMTD maximal tolerance doseCDC25 cell division cycle 25HIF-1α hypoxia-inducible factor 1 αMST microscale thermophoresisIC50 50% inhibition concentrationMFP M phase promoting factorPARP-1 poly(ADP-ribose) polymerase-10302 clinical medicineFOXO forkhead box ONec-1 necrostatin 1CDC2 cell division cycle protein 2 homologGeneral Pharmacology Toxicology and PharmaceuticsMitotic catastropheCDK cyclin-dependent kinase0303 health sciencesChemistryPolo-like kinaseMono-targeted therapyCell cycleBUBR1 budding uninhibited by benzimidazole-related 1Polo box domain030220 oncology & carcinogenesisPLK1 Polo-like kinaseNecroptosisSpindle damagePLK1IHC immunohistochemistryOriginal articleNecroptosisCell cyclePLK1APC/C anaphase-promoting complex/cyclosomePLK3ABC avidin-biotin complexPI propidium iodide03 medical and health sciencesFBS fetal bovine serumPDB Protein Data BankKd the dissociation constantKinase activity030304 developmental biologyAkt/PKB signaling pathwayCell growthlcsh:RM1-950LC3 light chain 3lcsh:Therapeutics. PharmacologyCancer researchDAPKs death-associated protein kinase3-MA 3-methyladenineDAPI 4′6-diamidino-2-phenylindoleSAC spindle assembly checkpointActa Pharmaceutica Sinica B
researchProduct

Los caballos en la Cova del Parpalló (Gandía, Valencia)

2005

Se estudian 165 plaquetas grabadas de la Cova del Parpalló, de las que 115 contienen una o varias representaciones de caballos que siguen las mismas grandes tendencias sugeridas por Villaverde. Es posible, con todo, señalar la existencia de dos subtendencias: por un lado un creciente grosor de los trazos, y por otro la consecución del volumen a través de trazos múltiples y repetidos. La tendencia a desarrollar el volumen está en correlación con el alargamiento del cuello y la representación dinámica del pecho, mediante una línea oblicua proyectada hacia adelante. Nuestra intención es, además, poner de manifiesto las concomitancias que se registran en el Solutro-gravetiense entre los cambios…

Parpalló cavedynamicNerjaParpalló cave; horse; plaquettes; stylistic criterion; dynamic; projected; Ardales; NerjaPrehistoriaplaquetteslcsh:Auxiliary sciences of historyhorseprojectedlcsh:Clcsh:Archaeologylcsh:CC1-960stylistic criterionArdalesSagvntum
researchProduct